← 返回前沿论文

携带新型 CD137 免疫检查点刺激剂激动剂的溶瘤腺病毒抑制肿瘤生长

英文原题:Oncolytic Adenovirus Armed with a Novel Agonist of the CD137 Immune Checkpoint Stimulator Suppresses Tumor Growth.

查看英文原题

Oncolytic Adenovirus Armed with a Novel Agonist of the CD137 Immune Checkpoint Stimulator Suppresses Tumor Growth.

PubMed 2024/03/21(内容时间) Vaccines (Basel) Q2 · IF 3.5(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

中文摘要

天然4-1BBL(CD137L)是一种细胞膜结合蛋白,对CD8+ T细胞的扩增、效应功能和存活至关重要。我们曾报道了一种具有活性的可溶性寡聚体构建体SA-4-1BBL的生成,并在多种小鼠肿瘤模型中证明了其免疫预防和免疫治疗疗效。

在此,我们开发了一种溶瘤腺病毒(OAd),用于将SA-4-1BBL(OAdSA-4-1BBL)递送并表达于实体瘤中以进行免疫治疗。该构建体表达的SA-4-1BBL蛋白在体外可促进T细胞增殖。OAdSA-4-1BBL降低了两种小鼠肺癌细胞系TC-1和CMT64的细胞活力,但未降低非癌性肺MM14.Lu细胞系的细胞活力。OAdSA-4-1BBL诱导了I型和II型程序性细胞死亡(分别为凋亡和自噬),并且还检测到自噬介导的三磷酸腺苷(ATP)释放。瘤内注射OAdSA-4-1BBL可在肿瘤中有效表达SA-4-1BBL蛋白,从而在同基因皮下TC-1小鼠肺癌模型中产生显著的肿瘤抑制。肿瘤抑制与树突状细胞频率升高以及细胞毒性CD8+ T细胞和NK细胞向肿瘤的浸润增加相关。

我们的数据表明,OAdSA-4-1BBL作为一种单独构建体或与其他免疫治疗方式(如免疫检查点抑制剂)联合使用,可能为肺癌提供一种有效的替代治疗策略。

展开英文摘要原文

Natural 4-1BBL (CD137L) is a cell membrane-bound protein critical to the expansion, effector function, and survival of CD8 + T cells.

We reported the generation of an active soluble oligomeric construct, SA-4-1BBL, with demonstrated immunoprevention and immunotherapeutic efficacy in various mouse tumor models.

Herein, we developed an oncolytic adenovirus (OAd) for the delivery and expression of SA-4-1BBL (OAdSA-4-1BBL) into solid tumors for immunotherapy. SA-4-1BBL protein expressed by this construct produced T-cell proliferation in vitro. OAdSA-4-1BBL decreased cell viability in two mouse lung cancer cell lines, TC-1 and CMT64, but not in the non-cancerous lung MM14. Lu cell line.

OAdSA-4-1BBL induced programmed cell death types I and II (apoptosis and autophagy, respectively), and autophagy-mediated adenosine triphosphate (ATP) release was also detected. Intratumoral injection of OAdSA-4-1BBL efficiently expressed the SA-4-1BBL protein in the tumors, resulting in significant tumor suppression in a syngeneic subcutaneous TC-1 mouse lung cancer model. Tumor suppression was associated with a higher frequency of dendritic cells and an increased infiltration of cytotoxic CD8 + T and NK cells into the tumors.

Our data suggest that OAdSA-4-1BBL may present an efficacious alternative therapeutic strategy against lung cancer as a standalone construct or in combination with other immunotherapeutic modalities, such as immune checkpoint inhibitors.

论文信息

作者
Ramos-Gonzalez MR、Tarique M、Batra L、Arguc F、Garza-Morales R、Shirwan H、Yolcu ES、Gomez-Gutierrez JG
单位
Roy Blunt NextGen Precision Health Building, University of Missouri, Columbia, MO 65211, USA.United States
期刊
Vaccines2024 Mar 21
原文标识
PubMed 38543974 · DOI 10.3390/vaccines12030340